ArticleAmerican journal of cancer research2025
Clinical efficacy and influencing factors of intensity-modulated radiation therapy in the treatment of sinonasal cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the clinical response of intensity-modulated radiation therapy (IMRT) in advanced sinonasal cancer (SNC), and to investigate the clinicopathological factors influencing treatment outcomes.
methodsA retrospective analysis was conducted on data from 110 patients with advanced SNC admitted between 2016 and 2020. After balancing baseline characteristics through propensity score matching, 96 patients were included in the analysis and divided into an observation group (OG, n=48) and a control group (CG, n=48). OG received IMRT combined with docetaxel and cisplatin chemotherapy, while CG received IMRT alone. Clinical data, molecular biomarker expression levels, and remedy outcomes were compared. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify factors influencing patients' overall survival (OS).
resultsNo significant differences existed in baseline characteristics between groups (all
conclusionIMRT combined with docetaxel and cisplatin chemotherapy significantly improves the prognosis of advanced SNC. Treatment modality, patient age, tumor differentiation, lymph node status, and molecular markers are all independent prognostic factors, indicating the potential for individualized treatment strategies under comprehensive assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.